APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Non-GMP Development

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non-GMP Development Market Analysis and Forecast 2026-2032

Report ID 17419828026 March 2026204 pages

Choose your research edition.

Industry ResearchNon-GMP Development Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-GMP Development Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Non-GMP Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-GMP Development Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-GMP Development Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Non-GMP Development market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non-GMP Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non-GMP Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non-GMP Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non-GMP Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non-GMP Development include Almac, GTP Technology, Alfa Aesar, Sundia-Manufacturing, J-STAR Research Inc., Lonza, AmbioPharm, Velesco and CordenPharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non-GMP Development, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non-GMP Development, also provides the revenue of main regions and countries. Of the upcoming market potential for Non-GMP Development, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non-GMP Development revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non-GMP Development market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non-GMP Development revenue, projected growth trends, production technology, application and end-user industry.

Non-GMP Development Segment by Company

Almac

GTP Technology

Alfa Aesar

Sundia-Manufacturing

J-STAR Research Inc.

Lonza

AmbioPharm

Velesco

CordenPharma

Piramal Pharma Solutions

Norwich

Aurigene Pharmaceutical Services

Actylis

CARBOGEN AMCIS

GTP Bioways

Symeres

Quotient Sciences

Non-GMP Development Segment by Type

Research Grade

Animal Free Grade

Non-GMP Development Segment by Application

Commercial & Academic

Clinical

Others

Non-GMP Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-GMP Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-GMP Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-GMP Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non-GMP Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non-GMP Development company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-GMP Development revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non-GMP Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Research Grade Major Player Table 3. Animal Free Grade Major Player Table 4. Global Non-GMP Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Commercial & Academic Major Player Table 6. Clinical Major Player Table 7. Others Major Player Table 8. Non-GMP Development Industry Trends Table 9. Non-GMP Development Industry Drivers Table 10. Non-GMP Development Industry Opportunities and Challenges Table 11. Non-GMP Development Industry Restraints Table 12. Global Non-GMP Development Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Non-GMP Development Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Non-GMP Development Market Share by Region (2021-2026) Table 15. Global Non-GMP Development Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Non-GMP Development Market Share by Region (2027-2032) Table 17. Global Non-GMP Development Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Non-GMP Development Revenue Market Share by Players (2021-2026) Table 19. Global Non-GMP Development Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Non-GMP Development Key Players Headquarters & Area Served Table 21. Global Non-GMP Development Players, Product Type & Application Table 22. Global Non-GMP Development Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Non-GMP Development by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Non-GMP Development Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Non-GMP Development Revenue Market Share by Type (2021-2026) Table 29. Global Non-GMP Development Revenue Market Share by Type (2027-2032) Table 30. Global Non-GMP Development Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Non-GMP Development Revenue Market Share by Application (2021-2026) Table 34. Global Non-GMP Development Revenue Market Share by Application (2027-2032) Table 35. Almac Company Information Table 36. Almac Business Overview Table 37. Almac Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Almac Non-GMP Development Product Portfolio Table 39. Almac Recent Development Table 40. GTP Technology Company Information Table 41. GTP Technology Business Overview Table 42. GTP Technology Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GTP Technology Non-GMP Development Product Portfolio Table 44. GTP Technology Recent Development Table 45. Alfa Aesar Company Information Table 46. Alfa Aesar Business Overview Table 47. Alfa Aesar Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Alfa Aesar Non-GMP Development Product Portfolio Table 49. Alfa Aesar Recent Development Table 50. Sundia-Manufacturing Company Information Table 51. Sundia-Manufacturing Business Overview Table 52. Sundia-Manufacturing Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sundia-Manufacturing Non-GMP Development Product Portfolio Table 54. Sundia-Manufacturing Recent Development Table 55. J-STAR Research Inc. Company Information Table 56. J-STAR Research Inc. Business Overview Table 57. J-STAR Research Inc. Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. J-STAR Research Inc. Non-GMP Development Product Portfolio Table 59. J-STAR Research Inc. Recent Development Table 60. Lonza Company Information Table 61. Lonza Business Overview Table 62. Lonza Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Lonza Non-GMP Development Product Portfolio Table 64. Lonza Recent Development Table 65. AmbioPharm Company Information Table 66. AmbioPharm Business Overview Table 67. AmbioPharm Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AmbioPharm Non-GMP Development Product Portfolio Table 69. AmbioPharm Recent Development Table 70. Velesco Company Information Table 71. Velesco Business Overview Table 72. Velesco Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Velesco Non-GMP Development Product Portfolio Table 74. Velesco Recent Development Table 75. CordenPharma Company Information Table 76. CordenPharma Business Overview Table 77. CordenPharma Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. CordenPharma Non-GMP Development Product Portfolio Table 79. CordenPharma Recent Development Table 80. Piramal Pharma Solutions Company Information Table 81. Piramal Pharma Solutions Business Overview Table 82. Piramal Pharma Solutions Non-GMP Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Piramal Pharma Solutions Non-GMP Development Product Portfolio Table 84. Piramal Pharma Solutions Recent Development Table 85. Norwich Company Information Table 86. Norwich Business Overview Table 87. Norwich Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Norwich Non-GMP Development Product Portfolio Table 89. Norwich Recent Development Table 90. Aurigene Pharmaceutical Services Company Information Table 91. Aurigene Pharmaceutical Services Business Overview Table 92. Aurigene Pharmaceutical Services Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Aurigene Pharmaceutical Services Non-GMP Development Product Portfolio Table 94. Aurigene Pharmaceutical Services Recent Development Table 95. Actylis Company Information Table 96. Actylis Business Overview Table 97. Actylis Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Actylis Non-GMP Development Product Portfolio Table 99. Actylis Recent Development Table 100. CARBOGEN AMCIS Company Information Table 101. CARBOGEN AMCIS Business Overview Table 102. CARBOGEN AMCIS Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. CARBOGEN AMCIS Non-GMP Development Product Portfolio Table 104. CARBOGEN AMCIS Recent Development Table 105. GTP Bioways Company Information Table 106. GTP Bioways Business Overview Table 107. GTP Bioways Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. GTP Bioways Non-GMP Development Product Portfolio Table 109. GTP Bioways Recent Development Table 110. Symeres Company Information Table 111. Symeres Business Overview Table 112. Symeres Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Symeres Non-GMP Development Product Portfolio Table 114. Symeres Recent Development Table 115. Quotient Sciences Company Information Table 116. Quotient Sciences Business Overview Table 117. Quotient Sciences Non-GMP Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Quotient Sciences Non-GMP Development Product Portfolio Table 119. Quotient Sciences Recent Development Table 120. North America Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 121. North America Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 122. North America Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 123. North America Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 124. North America Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. North America Non-GMP Development Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Non-GMP Development Revenue by Country (US$ Million) & (2027-2032) Table 127. Europe Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 130. Europe Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 131. Europe Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Europe Non-GMP Development Revenue by Country (2021-2026) & (US$ Million) Table 133. Europe Non-GMP Development Revenue by Country (US$ Million) & (2027-2032) Table 134. China Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 135. China Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 136. China Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 137. China Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 139. Asia Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 140. Asia Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 141. Asia Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Non-GMP Development Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Asia Non-GMP Development Revenue by Region (US$ Million) & (2021-2026) Table 144. Asia Non-GMP Development Revenue by Region (US$ Million) & (2027-2032) Table 145. SAMEA Non-GMP Development Revenue by Type (2021-2026) & (US$ Million) Table 146. SAMEA Non-GMP Development Revenue by Type (2027-2032) & (US$ Million) Table 147. SAMEA Non-GMP Development Revenue by Application (2021-2026) & (US$ Million) Table 148. SAMEA Non-GMP Development Revenue by Application (2027-2032) & (US$ Million) Table 149. SAMEA Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. SAMEA Non-GMP Development Revenue by Country (2021-2026) & (US$ Million) Table 151. SAMEA Non-GMP Development Revenue by Country (US$ Million) & (2027-2032) Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Non-GMP Development Image Figure 2. Global Non-GMP Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-GMP Development Market Size Share 2021 VS 2025 VS 2032 Figure 4. Research Grade Image Figure 5. Animal Free Grade Image Figure 6. Global Non-GMP Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Non-GMP Development Market Size Share 2021 VS 2025 VS 2032 Figure 8. Commercial & Academic Image Figure 9. Clinical Image Figure 10. Others Image Figure 11. Global Non-GMP Development Market Size (US$ Million) & (2021-2032) Figure 12. Global Non-GMP Development Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Non-GMP Development Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Non-GMP Development Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Non-GMP Development Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Non-GMP Development Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Non-GMP Development Revenue Market Share by Type (2021-2032) Figure 19. Global Non-GMP Development Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-GMP Development Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Non-GMP Development Revenue Market Share by Application (2021-2032) Figure 22. North America Non-GMP Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Non-GMP Development Revenue Share by Type (2021-2032) Figure 24. North America Non-GMP Development Revenue Share by Application (2021-2032) Figure 25. North America Non-GMP Development Revenue Share by Country (2021-2032) Figure 26. United States Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Non-GMP Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Non-GMP Development Revenue Share by Type (2021-2032) Figure 31. Europe Non-GMP Development Revenue Share by Application (2021-2032) Figure 32. Europe Non-GMP Development Revenue Share by Country (2021-2032) Figure 33. Germany Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Non-GMP Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Non-GMP Development Revenue Share by Type (2021-2032) Figure 43. China Non-GMP Development Revenue Share by Application (2021-2032) Figure 44. Asia Non-GMP Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Non-GMP Development Revenue Share by Type (2021-2032) Figure 46. Asia Non-GMP Development Revenue Share by Application (2021-2032) Figure 47. Asia Non-GMP Development Revenue Share by Region (2021-2032) Figure 48. Japan Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Non-GMP Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Non-GMP Development Revenue Share by Type (2021-2032) Figure 56. SAMEA Non-GMP Development Revenue Share by Application (2021-2032) Figure 57. SAMEA Non-GMP Development Revenue Share by Country (2021-2032) Figure 58. Brazil Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Non-GMP Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Research Grade
  • Animal Free Grade
Applications
  • Commercial & Academic
  • Clinical
  • Others
Companies covered
  • Almac
  • GTP Technology
  • Alfa Aesar
  • Sundia-Manufacturing
  • J-STAR Research Inc.
  • Lonza
  • AmbioPharm
  • Velesco
  • CordenPharma
  • Piramal Pharma Solutions
  • Norwich
  • Aurigene Pharmaceutical Services
  • Actylis
  • CARBOGEN AMCIS
  • GTP Bioways
  • Symeres
  • Quotient Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non-GMP Development Market by Type
  3. 1.2.1 Global Non-GMP Development Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Research Grade
  5. 1.2.3 Animal Free Grade
  6. 1.3 Non-GMP Development Market by Application
  7. 1.3.1 Global Non-GMP Development Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Commercial & Academic
  9. 1.3.3 Clinical
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Non-GMP Development Market Dynamics
  1. 2.1 Non-GMP Development Industry Trends
  2. 2.2 Non-GMP Development Industry Drivers
  3. 2.3 Non-GMP Development Industry Opportunities and Challenges
  4. 2.4 Non-GMP Development Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non-GMP Development Market Perspective (2021-2032)
  2. 3.2 Global Non-GMP Development Growth Trends by Region
  3. 3.2.1 Global Non-GMP Development Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non-GMP Development Market Size by Region (2021-2026)
  5. 3.2.3 Global Non-GMP Development Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non-GMP Development Revenue by Players
  2. 4.1.1 Global Non-GMP Development Revenue by Players (2021-2026)
  3. 4.1.2 Global Non-GMP Development Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non-GMP Development Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non-GMP Development Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non-GMP Development Key Players Headquarters & Area Served
  7. 4.4 Global Non-GMP Development Players, Product Type & Application
  8. 4.5 Global Non-GMP Development Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non-GMP Development Market CR5 and HHI
  11. 4.6.3 2025 Non-GMP Development Tier 1, Tier 2, and Tier 3
5 Non-GMP Development Market Size by Type
  1. 5.1 Global Non-GMP Development Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non-GMP Development Revenue by Type (2021-2032)
  3. 5.3 Global Non-GMP Development Revenue Market Share by Type (2021-2032)
6 Non-GMP Development Market Size by Application
  1. 6.1 Global Non-GMP Development Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non-GMP Development Revenue by Application (2021-2032)
  3. 6.3 Global Non-GMP Development Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Almac
  2. 7.1.1 Almac Company Information
  3. 7.1.2 Almac Business Overview
  4. 7.1.3 Almac Non-GMP Development Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Almac Non-GMP Development Product Portfolio
  6. 7.1.5 Almac Recent Developments
  7. 7.2 GTP Technology
  8. 7.2.1 GTP Technology Company Information
  9. 7.2.2 GTP Technology Business Overview
  10. 7.2.3 GTP Technology Non-GMP Development Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GTP Technology Non-GMP Development Product Portfolio
  12. 7.2.5 GTP Technology Recent Developments
  13. 7.3 Alfa Aesar
  14. 7.3.1 Alfa Aesar Company Information
  15. 7.3.2 Alfa Aesar Business Overview
  16. 7.3.3 Alfa Aesar Non-GMP Development Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Alfa Aesar Non-GMP Development Product Portfolio
  18. 7.3.5 Alfa Aesar Recent Developments
  19. 7.4 Sundia-Manufacturing
  20. 7.4.1 Sundia-Manufacturing Company Information
  21. 7.4.2 Sundia-Manufacturing Business Overview
  22. 7.4.3 Sundia-Manufacturing Non-GMP Development Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sundia-Manufacturing Non-GMP Development Product Portfolio
  24. 7.4.5 Sundia-Manufacturing Recent Developments
  25. 7.5 J-STAR Research Inc.
  26. 7.5.1 J-STAR Research Inc. Company Information
  27. 7.5.2 J-STAR Research Inc. Business Overview
  28. 7.5.3 J-STAR Research Inc. Non-GMP Development Revenue and Gross Margin (2021-2026)
  29. 7.5.4 J-STAR Research Inc. Non-GMP Development Product Portfolio
  30. 7.5.5 J-STAR Research Inc. Recent Developments
  31. 7.6 Lonza
  32. 7.6.1 Lonza Company Information
  33. 7.6.2 Lonza Business Overview
  34. 7.6.3 Lonza Non-GMP Development Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lonza Non-GMP Development Product Portfolio
  36. 7.6.5 Lonza Recent Developments
  37. 7.7 AmbioPharm
  38. 7.7.1 AmbioPharm Company Information
  39. 7.7.2 AmbioPharm Business Overview
  40. 7.7.3 AmbioPharm Non-GMP Development Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AmbioPharm Non-GMP Development Product Portfolio
  42. 7.7.5 AmbioPharm Recent Developments
  43. 7.8 Velesco
  44. 7.8.1 Velesco Company Information
  45. 7.8.2 Velesco Business Overview
  46. 7.8.3 Velesco Non-GMP Development Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Velesco Non-GMP Development Product Portfolio
  48. 7.8.5 Velesco Recent Developments
  49. 7.9 CordenPharma
  50. 7.9.1 CordenPharma Company Information
  51. 7.9.2 CordenPharma Business Overview
  52. 7.9.3 CordenPharma Non-GMP Development Revenue and Gross Margin (2021-2026)
  53. 7.9.4 CordenPharma Non-GMP Development Product Portfolio
  54. 7.9.5 CordenPharma Recent Developments
  55. 7.10 Piramal Pharma Solutions
  56. 7.10.1 Piramal Pharma Solutions Company Information
  57. 7.10.2 Piramal Pharma Solutions Business Overview
  58. 7.10.3 Piramal Pharma Solutions Non-GMP Development Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Piramal Pharma Solutions Non-GMP Development Product Portfolio
  60. 7.10.5 Piramal Pharma Solutions Recent Developments
  61. 7.11 Norwich
  62. 7.11.1 Norwich Company Information
  63. 7.11.2 Norwich Business Overview
  64. 7.11.3 Norwich Non-GMP Development Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Norwich Non-GMP Development Product Portfolio
  66. 7.11.5 Norwich Recent Developments
  67. 7.12 Aurigene Pharmaceutical Services
  68. 7.12.1 Aurigene Pharmaceutical Services Company Information
  69. 7.12.2 Aurigene Pharmaceutical Services Business Overview
  70. 7.12.3 Aurigene Pharmaceutical Services Non-GMP Development Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Aurigene Pharmaceutical Services Non-GMP Development Product Portfolio
  72. 7.12.5 Aurigene Pharmaceutical Services Recent Developments
  73. 7.13 Actylis
  74. 7.13.1 Actylis Company Information
  75. 7.13.2 Actylis Business Overview
  76. 7.13.3 Actylis Non-GMP Development Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Actylis Non-GMP Development Product Portfolio
  78. 7.13.5 Actylis Recent Developments
  79. 7.14 CARBOGEN AMCIS
  80. 7.14.1 CARBOGEN AMCIS Company Information
  81. 7.14.2 CARBOGEN AMCIS Business Overview
  82. 7.14.3 CARBOGEN AMCIS Non-GMP Development Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CARBOGEN AMCIS Non-GMP Development Product Portfolio
  84. 7.14.5 CARBOGEN AMCIS Recent Developments
  85. 7.15 GTP Bioways
  86. 7.15.1 GTP Bioways Company Information
  87. 7.15.2 GTP Bioways Business Overview
  88. 7.15.3 GTP Bioways Non-GMP Development Revenue and Gross Margin (2021-2026)
  89. 7.15.4 GTP Bioways Non-GMP Development Product Portfolio
  90. 7.15.5 GTP Bioways Recent Developments
  91. 7.16 Symeres
  92. 7.16.1 Symeres Company Information
  93. 7.16.2 Symeres Business Overview
  94. 7.16.3 Symeres Non-GMP Development Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Symeres Non-GMP Development Product Portfolio
  96. 7.16.5 Symeres Recent Developments
  97. 7.17 Quotient Sciences
  98. 7.17.1 Quotient Sciences Company Information
  99. 7.17.2 Quotient Sciences Business Overview
  100. 7.17.3 Quotient Sciences Non-GMP Development Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Quotient Sciences Non-GMP Development Product Portfolio
  102. 7.17.5 Quotient Sciences Recent Developments
8 North America
  1. 8.1 North America Non-GMP Development Revenue (2021-2032)
  2. 8.2 North America Non-GMP Development Revenue by Type (2021-2032)
  3. 8.2.1 North America Non-GMP Development Revenue by Type (2021-2026)
  4. 8.2.2 North America Non-GMP Development Revenue by Type (2027-2032)
  5. 8.3 North America Non-GMP Development Revenue Share by Type (2021-2032)
  6. 8.4 North America Non-GMP Development Revenue by Application (2021-2032)
  7. 8.4.1 North America Non-GMP Development Revenue by Application (2021-2026)
  8. 8.4.2 North America Non-GMP Development Revenue by Application (2027-2032)
  9. 8.5 North America Non-GMP Development Revenue Share by Application (2021-2032)
  10. 8.6 North America Non-GMP Development Revenue by Country
  11. 8.6.1 North America Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non-GMP Development Revenue by Country (2021-2026)
  13. 8.6.3 North America Non-GMP Development Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Non-GMP Development Revenue (2021-2032)
  2. 9.2 Europe Non-GMP Development Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non-GMP Development Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non-GMP Development Revenue by Type (2027-2032)
  5. 9.3 Europe Non-GMP Development Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non-GMP Development Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non-GMP Development Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non-GMP Development Revenue by Application (2027-2032)
  9. 9.5 Europe Non-GMP Development Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non-GMP Development Revenue by Country
  11. 9.6.1 Europe Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non-GMP Development Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non-GMP Development Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Non-GMP Development Revenue (2021-2032)
  2. 10.2 China Non-GMP Development Revenue by Type (2021-2032)
  3. 10.2.1 China Non-GMP Development Revenue by Type (2021-2026)
  4. 10.2.2 China Non-GMP Development Revenue by Type (2027-2032)
  5. 10.3 China Non-GMP Development Revenue Share by Type (2021-2032)
  6. 10.4 China Non-GMP Development Revenue by Application (2021-2032)
  7. 10.4.1 China Non-GMP Development Revenue by Application (2021-2026)
  8. 10.4.2 China Non-GMP Development Revenue by Application (2027-2032)
  9. 10.5 China Non-GMP Development Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non-GMP Development Revenue (2021-2032)
  2. 11.2 Asia Non-GMP Development Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non-GMP Development Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non-GMP Development Revenue by Type (2027-2032)
  5. 11.3 Asia Non-GMP Development Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non-GMP Development Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non-GMP Development Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non-GMP Development Revenue by Application (2027-2032)
  9. 11.5 Asia Non-GMP Development Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non-GMP Development Revenue by Country
  11. 11.6.1 Asia Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non-GMP Development Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non-GMP Development Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non-GMP Development Revenue (2021-2032)
  2. 12.2 SAMEA Non-GMP Development Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non-GMP Development Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non-GMP Development Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non-GMP Development Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non-GMP Development Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non-GMP Development Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non-GMP Development Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non-GMP Development Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non-GMP Development Revenue by Country
  11. 12.6.1 SAMEA Non-GMP Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non-GMP Development Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non-GMP Development Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst